Pharma Giant Signs Deal to Manufacture Drugs in Orbit, Marking First Commercial Space Manufacturing Pact

By

A startup aiming to produce pharmaceuticals in outer space has secured its first major commercial partner, signaling a milestone for orbital manufacturing. Varda Space Industries announced it has signed United Therapeutics to launch drugs into microgravity to form novel crystal structures.

The agreement represents what Varda calls 'the first commercial path to products made in space,' according to Michael Reilly, the company's chief strategy officer. United Therapeutics CEO Martine Rothblatt, a satellite veteran, said orbital conditions could yield 'even more amazing' versions of existing medicines.

Background

Previously, small-scale experiments on the International Space Station tested how weightlessness affects chemical mixtures—water becomes a wobbly sphere when gravity is absent. Now, Varda plans to send United Therapeutics' drugs into orbit so they can crystallize under microgravity, potentially creating atomic arrangements impossible on Earth.

Varda, based in El Segundo, California, was founded in 2021 by Delian Asparouhov and former SpaceX engineer Will Bruey. The company bets that falling launch costs and frequent rocket flights will make it profitable to ship raw materials into space, process them, and return the finished products to Earth.

What This Means

Pharmaceutical companies often reformulate blockbuster drugs to extend patent protection—switching from pills to inhalers, for example. United Therapeutics has used this strategy for lung disease drugs. Now Varda positions itself as a reformulation partner using orbital facilities instead of terrestrial technologies like nebulizers or nanoparticles.

If successful, this partnership could open a new frontier for drug development. The hope is that microgravity crystals exhibit superior stability or other valuable properties, yielding 'improved versions' that keep imitators at bay. However, the concept remains unproven at commercial scale.

This is a breaking news story. Updates will follow as more details emerge.

Related Articles

• How to Assess Your Eating Triggers to Predict GLP-1 Drug Effectiveness
• Preserving the American Dream: Addressing Economic Inequality and Civic Engagement
• A DNA-Based Revolution in Cholesterol Management: Answers to Key Questions
• Angelini Pharma Acquires Catalyst Pharmaceuticals in $4.1B Cash Deal to Expand U.S. Neurology Portfolio
• From Nuclear Waste to Lifesaving Drugs: The Race to Secure Radioactive Isotopes
• 6 Critical Facts About PFAS Contamination in Infant Formula
• Mastering Log Cost Control: A Practical Guide to Using Adaptive Logs Drop Rules
• Beyond GLP-1: Experimental Obesity Drug Targets Five Pathways in Mice